$2.85
-0.08 (-2.73%)
Open$2.92
Previous Close$2.93
Day High$2.98
Day Low$2.81
52W High$11.37
52W Low$2.87
Volume—
Avg Volume224.0K
Market Cap28.93M
P/E Ratio—
EPS$-13.02
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+410.2% upside
Current
$2.85
$2.85
Target
$14.54
$14.54
$12.76
$14.54 avg
$24.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.25M | 5.50M | 4.94M |
| Net Income | 1.19M | 1.50M | 1.15M |
| Profit Margin | 22.6% | 27.2% | 23.3% |
| EBITDA | 2.24M | 2.36M | 2.10M |
| Free Cash Flow | 844.4K | 896.3K | 789.1K |
| Rev Growth | +6.7% | -8.7% | -5.9% |
| Debt/Equity | 0.59 | 0.52 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |